New Japan Approvals Include Tafinlar, Tagrisso
This article was originally published in PharmAsia News
Executive Summary
The latest batch of drug approvals in Japan includes several novel oncology products, some of which have only recently been launched elsewhere, in a sign that applicants and regulators are trying to speed up local access to important new therapies.
You may also be interested in...
Japan Approval Another Boost For Tagrisso in 1L NSCLC
Following a priority review, Japan has approved AstraZeneca’s Tagrisso for the first-line treatment of inoperable or recurrent EGFR mutation-positive NSCLC, further strengthening the drug’s position in this setting.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.